$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

$csbr Overview Financials Valuation SEC Filings Company Website

2020 Q3 Form 10-Q Financial Statement

#000162828020013559 Filed on September 14, 2020

Income Statement

Concept	2020 Q3	2019 Q3
Revenue	$9.547M	$6.737M
YoY Change	41.71%	8.22%
Cost Of Revenue	$5.336M	$3.752M
YoY Change	42.22%	21.7%
Gross Profit	$4.211M	$2.985M
YoY Change	41.07%	-5.0%
Gross Profit Margin	44.11%	44.31%
Selling, General & Admin	$2.590M	$2.296M
YoY Change	12.8%	45.96%
% of Gross Profit	61.51%	76.92%
Research & Development	$1.597M	$1.303M
YoY Change	22.56%	19.76%
% of Gross Profit	37.92%	43.65%
Depreciation & Amortization	$224.0K	$145.0K
YoY Change	54.48%	30.63%
% of Gross Profit	5.32%	4.86%
Operating Expenses	$4.187M	$7.351M
YoY Change	-43.04%	27.98%
Operating Profit	$24.00K	-$614.0K
YoY Change	-103.91%	-227.65%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$64.00K	-$12.00K
YoY Change	-633.33%	-1300.0%
Pretax Income	$88.00K	-$626.0K
YoY Change	-114.06%	-229.88%
Income Tax	$13.00K	$15.00K
% Of Pretax Income	14.77%
Net Earnings	$75.00K	-$641.0K
YoY Change	-111.7%	-232.71%
Net Earnings / Revenue	0.79%	-9.51%
Basic Earnings Per Share	$0.01	-$0.06
Diluted Earnings Per Share	$0.01	-$0.06
COMMON SHARES
Basic Shares Outstanding	12.73M shares	11.62M shares
Diluted Shares Outstanding	14.23M shares	11.62M shares

Balance Sheet

Concept	2020 Q3	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.940M	$2.200M
YoY Change	215.45%	115.69%
Cash & Equivalents	$6.943M	$2.202M
Short-Term Investments
Other Short-Term Assets	$360.0K	$260.0K
YoY Change	38.46%	4.0%
Inventory
Prepaid Expenses
Receivables	$5.039M	$3.891M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$12.34M	$6.349M
YoY Change	94.39%	26.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.434M	$3.113M
YoY Change	42.43%	28.37%
Goodwill	$335.0K	$669.0K
YoY Change	-49.93%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$36.00K	$128.0K
YoY Change	-71.88%	10.34%
Total Long-Term Assets	$10.48M	$7.013M
YoY Change	49.41%	108.72%
TOTAL ASSETS
Total Short-Term Assets	$12.34M	$6.349M
Total Long-Term Assets	$10.48M	$7.013M
Total Assets	$22.82M	$13.36M
YoY Change	70.78%	59.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.675M	$2.725M
YoY Change	-1.83%	28.6%
Accrued Expenses	$2.154M	$770.0K
YoY Change	179.74%	110.38%
Deferred Revenue	$5.669M	$3.969M
YoY Change	42.83%	-6.9%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$70.00K	$10.00K
YoY Change	600.0%	-92.86%
Total Short-Term Liabilities	$11.09M	$7.930M
YoY Change	39.79%	15.18%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$178.0K	$151.0K
YoY Change	17.88%	0.0%
Total Long-Term Liabilities	$178.0K	$151.0K
YoY Change	17.88%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.09M	$7.930M
Total Long-Term Liabilities	$178.0K	$151.0K
Total Liabilities	$17.31M	$11.63M
YoY Change	48.76%	49.36%
SHAREHOLDERS EQUITY
Retained Earnings	-$72.60M	-$71.30M
YoY Change	1.82%	1.36%
Common Stock	$78.11M	$73.07M
YoY Change	6.9%	1.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.513M	$1.728M
YoY Change
Total Liabilities & Shareholders Equity	$22.82M	$13.36M
YoY Change	70.78%	59.24%

Cashflow Statement

Concept	2020 Q3	2019 Q3
OPERATING ACTIVITIES
Net Income	$75.00K	-$641.0K
YoY Change	-111.7%	-232.71%
Depreciation, Depletion And Amortization	$224.0K	$145.0K
YoY Change	54.48%	30.63%
Cash From Operating Activities	-$715.0K	-$279.0K
YoY Change	156.27%	-183.04%
INVESTING ACTIVITIES
Capital Expenditures	$718.0K	$749.0K
YoY Change	-4.14%	254.98%
Acquisitions
YoY Change
Other Investing Activities	$90.00K
YoY Change
Cash From Investing Activities	-$626.0K	-$749.0K
YoY Change	-16.42%	254.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$58.00K	-$7.000K
YoY Change	728.57%	-120.0%
NET CHANGE
Cash From Operating Activities	-$715.0K	-$279.0K
Cash From Investing Activities	-$626.0K	-$749.0K
Cash From Financing Activities	-$58.00K	-$7.000K
Net Change In Cash	-$1.399M	-$1.035M
YoY Change	35.17%	-746.88%
FREE CASH FLOW
Cash From Operating Activities	-$715.0K	-$279.0K
Capital Expenditures	$718.0K	$749.0K
Free Cash Flow	-$1.433M	-$1.028M
YoY Change	39.4%	-922.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q2	csbr	Assetsin Progress Gross AssetsinProgressGross	554000	USD
CY2020Q3	csbr	Assetsin Progress Gross AssetsinProgressGross	114000	USD
CY2018Q3	csbr	Finance Lease Cost FinanceLeaseCost	266000	USD
CY2019Q4	csbr	Finance Lease Cost FinanceLeaseCost	231000	USD
	csbr	Finance Lease Cost FinanceLeaseCost	149000	USD
CY2018Q3	csbr	Finance Lease Monthly Payment FinanceLeaseMonthlyPayment	11000	USD
CY2019Q4	csbr	Finance Lease Monthly Payment FinanceLeaseMonthlyPayment	19000	USD
CY2019Q3	csbr	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	42000	USD
CY2020Q3	csbr	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-157000	USD
CY2019Q3	csbr	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	98000	USD
CY2020Q3	csbr	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-67000	USD
CY2020Q3	csbr	Lessee Operating Lease Liabilitytobe Paid After Year Four LesseeOperatingLeaseLiabilitytobePaidAfterYearFour	7268000	USD
CY2020Q3	csbr	Numberof Operating Subsidiaries NumberofOperatingSubsidiaries	2	subsidiary
CY2019Q4	csbr	Present Value Minimum Future Obligations Interest Rate PresentValueMinimumFutureObligationsInterestRate	0.0475
CY2019Q3	csbr	Proceeds From Refund Of Security Deposit ProceedsFromRefundOfSecurityDeposit	0	USD
CY2020Q3	csbr	Proceeds From Refund Of Security Deposit ProceedsFromRefundOfSecurityDeposit	92000	USD
CY2019Q3	csbr	Reversalof Provisionfor Doubtful Accounts ReversalofProvisionforDoubtfulAccounts	6000	USD
CY2020Q3	csbr	Reversalof Provisionfor Doubtful Accounts ReversalofProvisionforDoubtfulAccounts	-6000	USD
CY2020Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod	1235	shares
CY2020Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P9Y9M36D
CY2020Q3	csbr	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	4.95
CY2020Q3	csbr	Working Capital Deficit WorkingCapitalDeficit	-1300000	USD
CY2020Q3	dei	Amendment Flag AmendmentFlag	false
CY2020Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-30
CY2020Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2020Q3	dei	Document Period End Date DocumentPeriodEndDate	2020-07-31
CY2020Q3	dei	Document Type DocumentType	10-Q
CY2020Q3	dei	Entity Central Index Key EntityCentralIndexKey	0000771856
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12727888	shares
CY2020Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q3	dei	Entity Registrant Name EntityRegistrantName	CHAMPIONS ONCOLOGY, INC.
CY2020Q3	dei	Entity Shell Company EntityShellCompany	false
CY2020Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3140000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2675000	USD
CY2020Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	2655000	USD
CY2020Q3	us-gaap	Accounts Receivable Gross AccountsReceivableGross	2633000	USD
CY2020Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	5059000	USD
CY2020Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	5322000	USD
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4770000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5039000	USD
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2276263	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.24
CY2020Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.20
CY2020Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2154000	USD
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2772000	USD
CY2020Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3048000	USD
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2502000	USD
CY2020Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	77978000	USD
CY2020Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	78098000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	131000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	120000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	131000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	120000	USD
CY2020Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	289000	USD
CY2020Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	283000	USD
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4044648	shares
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2276263	shares
CY2020Q2	us-gaap	Assets Assets	20751000	USD
CY2020Q3	us-gaap	Assets Assets	22820000	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	13497000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	12342000	USD
CY2020Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1209000	USD
CY2020Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1689000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8342000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6943000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3237000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2202000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8342000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6943000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1035000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1399000	USD
CY2020Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	USD
CY2020Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	USD
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12726728	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12727888	shares
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12726728	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12727888	shares
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	13000	USD
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	13000	USD
CY2020Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	5815000	USD
CY2020Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	5669000	USD
CY2020Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5815000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5669000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3752000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5336000	USD
CY2019Q3	us-gaap	Depreciation Depreciation	145000	USD
CY2020Q3	us-gaap	Depreciation Depreciation	224000	USD
CY2019Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	182000	USD
CY2020Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	277000	USD
CY2020Q3	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	7400	USD
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2019Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	0	USD
CY2020Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	125000	USD
CY2020Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	72000	USD
CY2019Q4	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	77000	USD
CY2019Q3	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	7000	USD
CY2020Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	2000	USD
CY2020Q3	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	58000	USD
CY2020Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	366000	USD
CY2020Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	343000	USD
CY2020Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	53100	USD
CY2020Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	180000	USD
CY2020Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	238000	USD
CY2019Q3	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	0	USD
CY2020Q3	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	75000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1426000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1382000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	335000	USD
CY2020Q3	us-gaap	Goodwill Goodwill	335000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-626000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	88000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13000	USD
CY2019Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-82000	USD
CY2020Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-465000	USD
CY2019Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-480000	USD
CY2020Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	263000	USD
CY2019Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-410000	USD
CY2020Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-348000	USD
CY2019Q3	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-53000	USD
CY2020Q3	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-146000	USD
CY2019Q3	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2020Q3	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1000	USD
CY2019Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-52000	USD
CY2020Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-25000	USD
CY2019Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2020Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1504366	shares
CY2020Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	4000	USD
CY2020Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	4000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.061
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1117000	USD
CY2020Q2	us-gaap	Liabilities Liabilities	15433000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	15765000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1851000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1867000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1844000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1818000	USD
CY2020Q3	us-gaap	Liabilities Liabilities	17307000	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20751000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22820000	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	12085000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	11085000	USD
CY2020Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	4818000	USD
CY2020Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	5437000	USD
CY2019Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-7000	USD
CY2020Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-58000	USD
CY2019Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-749000	USD
CY2020Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-626000	USD
CY2019Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-279000	USD
CY2020Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-715000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-641000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	75000	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-641000	USD
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	75000	USD
CY2019Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	7351000	USD
CY2020Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	9523000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-614000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	24000	USD
CY2019Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	239000	USD
CY2020Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	307000	USD
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	457000	USD
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	503000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	515000	USD
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3553000	USD
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3170000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6044000	USD
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3103000	USD
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2798000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5673000	USD
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y5M1D
CY2020Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	128000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	36000	USD
CY2020Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	178000	USD
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	178000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	64000	USD
CY2019Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	749000	USD
CY2020Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	718000	USD
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	385000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	360000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6765000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7482000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3993000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4434000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1303000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1597000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-72673000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-72600000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-72598000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6737000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9547000	USD
CY2020Q3	us-gaap	Revenue Performance Obligation Description Of Timing RevenuePerformanceObligationDescriptionOfTiming	The majority of the Company's revenue arrangements are service contracts that are complete within a year or less. There are a few contracts that range in duration between 1 and 3 years.
CY2019Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3205000	USD
CY2020Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3872000	USD
CY2019Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	870000	USD
CY2020Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1208000	USD
CY2019Q3	us-gaap	Share Based Compensation ShareBasedCompensation	131000	USD
CY2020Q3	us-gaap	Share Based Compensation ShareBasedCompensation	120000	USD
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.0000
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7264
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0000
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0039
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1957682	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.85
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	500	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7500	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.85
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10663000	USD
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		USD
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2271658	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2276263	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.23
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.24
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		USD
CY2020Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.51
CY2020Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.94
CY2019Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y0M0D
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	11810000	USD
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y2M14D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y0M0D
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y9M21D
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y9M21D
CY2020Q3	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	1160	shares
CY2020Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1160	shares
CY2020Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	2238000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	1728000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	5318000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	5513000	USD
CY2020Q3	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	us-gaap:ServiceMember
CY2020Q3	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	us-gaap:ServiceMember
CY2020Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	2404000	USD
CY2020Q3	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	2689000	USD
CY2020Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	178000	USD
CY2020Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	178000	USD
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11619538	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14231641	shares
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11619538	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12727275	shares

Files In Submission

Name	View Source	Status
0001628280-20-013559-index-headers.html	Edgar Link	pending
0001628280-20-013559-index.html	Edgar Link	pending
0001628280-20-013559.txt	Edgar Link	pending
0001628280-20-013559-xbrl.zip	Edgar Link	pending
csbr-20200731.xml	Edgar Link	completed
csbr-20200731.xsd	Edgar Link	pending
csbr-20200731_cal.xml	Edgar Link	unprocessable
csbr-20200731_def.xml	Edgar Link	unprocessable
csbr-20200731_lab.xml	Edgar Link	unprocessable
csbr-20200731_pre.xml	Edgar Link	unprocessable
csbr10-q7312020.htm	Edgar Link	pending
csbrq1731202010-qex311.htm	Edgar Link	pending
csbrq1731202010-qex312.htm	Edgar Link	pending
csbrq1731202010-qex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

2020 Q3 Form 10-Q Financial Statement

#000162828020013559 Filed on September 14, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR CHAMPIONS ONCOLOGY, INC. Stock $csbr

2020 Q3 Form 10-Q Financial Statement

#000162828020013559 Filed on September 14, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr